

# Magdalena Korecka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8679321/publications.pdf>

Version: 2024-02-01

26  
papers

1,287  
citations

567144

15  
h-index

794469

19  
g-index

27  
all docs

27  
docs citations

27  
times ranked

1913  
citing authors

#	ARTICLE	IF	CITATIONS
1	Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. <i>Alzheimer's and Dementia</i> , 2010, 6, 230-238.	0.4	256
2	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 396.	4.5	146
3	Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid- $\beta$ 1-42 and $\beta$ , Proteins as Alzheimer Disease Biomarkers. <i>Clinical Chemistry</i> , 2013, 59, 903-916.	1.5	139
4	CSF A $\beta$ 1-42 – an excellent but complicated Alzheimer's biomarker – a route to standardisation. <i>Clinica Chimica Acta</i> , 2017, 467, 27-33.	0.5	104
5	Qualification of a Surrogate Matrix-Based Absolute Quantification Method for Amyloid- $\beta$ 42 in Human Cerebrospinal Fluid Using 2D UPLC-Tandem Mass Spectrometry. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 441-451.	1.2	94
6	Validation of Plasma Amyloid- $\beta$ 42/40 for Detecting Alzheimer Disease Amyloid Plaques. <i>Neurology</i> , 2022, 98, .	1.5	89
7	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. <i>Alzheimer's and Dementia</i> , 2015, 11, 772-791.	0.4	79
8	Improved protocol for measurement of plasma $\beta$ -amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. , 2012, 8, 250-260.		56
9	Derivation of cutoffs for the Elecsys <sup>®</sup> amyloid $\beta$ (1-42) assay in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 698-705.	1.2	50
10	Round robin test on quantification of amyloid- $\beta$ 1-42 in cerebrospinal fluid by mass spectrometry. <i>Alzheimer's and Dementia</i> , 2016, 12, 55-59.	0.4	46
11	First amyloid $\beta$ 1-42 certified reference material for re-calibrating commercial immunoassays. <i>Alzheimer's and Dementia</i> , 2020, 16, 1493-1503.	0.4	42
12	Sensitive, High Throughput HPLC-MS/MS Method With On-line Sample Clean-up for Everolimus Measurement. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 484-490.	1.0	38
13	Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids. <i>Journal of Neurochemistry</i> , 2021, 159, 211-233.	2.1	29
14	Effect of escitalopram dose and treatment duration on CSF A $\beta$ levels in healthy older adults. <i>Neurology</i> , 2020, 95, e2658-e2665.	1.5	28
15	Simultaneous HPLC-MS-MS quantification of 8-iso-PGF $_{2\alpha}$ and 8,12-iso-iPGF $_{2\alpha}$ in CSF and brain tissue samples with on-line cleanup. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2209-2216.	1.2	25
16	History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress. <i>Drug and Alcohol Dependence</i> , 2014, 142, 262-268.	1.6	25
17	Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method. <i>Clinical Chemistry</i> , 2020, 66, 587-597.	1.5	15
18	Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice. <i>Journal of Applied Laboratory Medicine</i> , The, 2020, 5, 183-193.	0.6	10

#	ARTICLE	IF	CITATIONS
19	P4-076: INCLUSION OF PATIENTS WITH ALZHEIMER'S DISEASE PATHOLOGY IN SOLANEZUMAB EXPEDITION 3 USING FLORBETAPIR PET IMAGING OR INNO-BIA ALZBIO3 CSF AÎ²1-42. , 2014, 10, P811-P811.		6
20	Review of the newest HPLC methods with mass spectrometry detection for determination of immunosuppressive drugs in clinical practice. Annals of Transplantation, 2009, 14, 61-72.	0.5	6
21	Quantitation of Sirolimus Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS). Methods in Molecular Biology, 2010, 603, 469-477.	0.4	3
22	P1-119: Prospective quality-control monitoring in the context of a clinical trial. , 2015, 11, P386-P387.		1
23	P2â€091: ASSAY PERFORMANCE MONITORING FOR AD BIOMARKERS USING POOLED CEREBROSPINAL FLUID. Alzheimer's and Dementia, 2018, 14, P702.	0.4	0
24	P1â€255: ANALYTICAL AND CLINICAL PERFORMANCE OF AMYLOID BETA PEPTIDES: MEASUREMENT IN CSF OF ADNI2 AND GO PARTICIPANTS BY A LCâ€MSâ€MS REFERENCE METHOD. Alzheimer's and Dementia, 2018, 14, P378.	0.4	0
25	Webâ€based requisitioning, tracking and laboratory result reporting system for clinical trials using a central laboratory. Alzheimer's and Dementia, 2020, 16, e038627.	0.4	0
26	Ultraâ€performance liquid chromatographyâ€tandem mass spectrometry method for analysis of tau in human cerebrospinal fluid without the need of immunocapture. Alzheimer's and Dementia, 2020, 16, e040373.	0.4	0